Preliminary Results Of A Phase 1 Dose Escalation Study Of The First-In-Class Igm Based Bispecific Antibody Igm2323 (Anti-Cd20 X Anti-Cd3) In Patients With Advanced B-Cell Malignancies
BLOOD（2020）
摘要
Introduction:
更多查看译文
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要